The stimulus package adds $27 billion to an emergency fund that could give a boost to dozens of projects by pharmaceutical companies and academic groups developing drugs and vaccines against coronavirus. The emergency fund received a smaller amount of funding under a coronavirus response act signed earlier in March.

The package allows the government to take steps to ensure that products developed with the emergency funding will be “affordable in the commercial market,” but that these steps shouldn’t delay development of the products.